Albany - NY, Oct. 20, 2015 (GLOBE NEWSWIRE) -- According to a new market report published by Transparency Market Research Spinal Muscular Atrophy Market: Pipeline Assessment, Size, Growth, Trends, and Forecast, 2015 - 2023" the spinal muscular atrophy marketphase three candidate ISIS-SMNRx is expected to generate total revenue of USD 0.47 billion by 2023.
Browse the full Spinal Muscular Atrophy Market: Pipeline Assessment, Size, Growth, Trends, and Forecast, 2015 - 2023 report at http://www.transparencymarketresearch.com/spinal-muscular-atrophy-market.html
Spinal muscular atrophy (SMA) is a hereditary autosomal recessive disease affecting areas of the nervous system that control voluntary muscle movement. SMA is identified as a leading genetic disorder causing mortality among infants. According to Orphanet, one infant in 6,000 births is estimated to suffer from SMA. Furthermore, over 10 million people in the U.S. are carriers of SMA gene. Depending on the age of onset and symptoms, spinal muscular atrophy is classified in four main types. Type 1 SMA is the most severe form, and affects infants aged between zero and six months. Over 60% of annual SMA cases are of type 1 SMA, wherein infants usually do not survive for more than 2 years. Type 2 SMA is a moderate form affecting children aged between six months and eighteen months. Patients with Type 3 SMA and Type 4 SMA usually have a normal lifespan.
Currently, no cure exists for spinal muscular atrophy, and treatment is directed towards managing common symptoms of SMA. Physiotherapy is strongly recommended in early stages of the disease to extend range of motion and improve muscle flexibility. Other treatment methods are targeted to treat gastrointestinal and respiratory disorders, which are common in SMA patients. The SMA pipeline is dry, with single drug in phase 3, three in phase 2, and one in phase 3 clinical trials. ISIS-SMNRx by Isis Pharmaceutical is an antisense drug that has shown promising results in phase 2 clinical trials. Phase 3 study of ISIS-SMNRx for treatment of Type 1 SMA and Type 2 SMA is expected to complete in 2016. In the United States, the drug is expected to reach annual sales of USD 0.47 billion by 2023. Olesoxime (TRO19622) has completed its phase2/3 trials, and has shown promising results, with potential to effectively treat type 2 and type 3 SMA. Other potential candidates include Olesoxime (TRO19622), LMI070, RO6885247, CK-2127107, scAAV9.CB.SMN and RG3039.
Get Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7187
The United States and Europe have higher percentage of diagnosed cases of SMA. Government and private organization in these regions are also involved in creating awareness about the disease. Higher confirmed carrier population would also help in faster market growth in these regions. Furthermore, government incentives for development of therapeutic alternatives for rare diseases also boosts research and development in the SMA landscape.Companies with potential candidates in the spinal muscular atrophy pipeline include AveXis, Inc., Cytokinetics, Inc., F. Hoffmann-La Roche Ltd., Novartis AG, and Isis Pharmaceuticals, Inc.
Spinal Muscular Atrophy Pipeline is segmented as below:
- Late Stage Candidates (Phase 3)
- ISIS-SMN Rx
- Early Stage Candidates (Phase 1 and Phase 2)
- Olesoxime (TRO19622)
- LMI070
- RO6885247
- CK-2127107
- CB.SMN
- RG3039
About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.